​

Vir Bio (VIR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VIR Stock Forecast

Vir Bio (VIR) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $21.29, with a high of $30.00 and a low of $18.00. This represents a 116.80% increase from the last price of $9.82.

$5 $10 $15 $20 $25 $30 High: $30 Avg: $21.29 Low: $18 Last Closed Price: $9.82

VIR Stock Rating

Vir Bio stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 2 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 10 0 Strong Sell Sell Hold Buy Strong Buy

VIR Price Target Upside V Benchmarks

TypeNameUpside
StockVir Bio116.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts81011
Avg Price Target$21.88$21.40$20.55
Last Closing Price$9.82$9.82$9.82
Upside/Downside122.81%117.92%109.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2637---10
Feb, 2646---10
Jan, 2646---10
Dec, 2546---10
Nov, 2555---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2026Patrick TrucchioH.C. Wainwright$20.00$9.13119.06%103.67%
Feb 26, 2026Roanna RuizLeerink Partners$20.00$9.33114.36%103.67%
Feb 24, 2026Barclays$30.00$9.49216.12%205.50%
Feb 24, 2026Cory KasimovEvercore ISI$18.00$9.7085.57%83.30%
Feb 24, 2026Joseph StringerNeedham$18.00$9.6486.72%83.30%
Feb 24, 2026Michael UlzMorgan Stanley$24.00$7.43223.01%144.40%
Feb 24, 2026Sean McCutcheonRaymond James$19.00$9.6996.08%93.48%
Feb 17, 2026Barclays$26.00$7.47248.06%164.77%
Feb 04, 2026Etzer DaroutBarclays$24.00$7.68212.50%144.40%
Dec 30, 2025Patrick TrucchioH.C. Wainwright$15.00$5.98150.84%52.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 04, 2026H.C. WainwrightBuyBuyhold
Feb 26, 2026Leerink PartnersOutperformOutperformhold
Feb 24, 2026BarclaysOverweightOverweighthold
Feb 24, 2026Evercore ISIOutperformOutperformhold
Feb 24, 2026NeedhamBuyBuyhold
Feb 24, 2026Morgan StanleyOverweightOverweighthold
Feb 24, 2026Raymond JamesOutperformStrong Buyupgrade
Feb 04, 2026BarclaysOverweightOverweighthold
Jan 13, 2026BenchmarkBuyBuyhold
Dec 30, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.07$3.89$-4.59$-3.83$-3.16---
Avg Forecast$2.70$4.31$-4.66$-3.88$-3.54$-3.44$-2.78$-1.92
High Forecast$5.09$7.98$-3.62$-3.66$-2.59$-2.96$-1.85$0.07
Low Forecast$1.42$1.79$-5.42$-3.98$-4.51$-4.01$-3.32$-3.90
Surprise %50.74%-9.74%-1.50%-1.29%-10.73%---

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.10B$1.62B$86.18M$74.20M$68.56M---
Avg Forecast$905.58M$1.71B$79.68M$68.66M$30.36M$32.45M$84.42M$289.68M
High Forecast$1.52B$2.83B$105.05M$95.87M$54.58M$33.17M$151.76M$520.71M
Low Forecast$573.97M$942.29M$68.07M$58.31M$6.20M$31.74M$17.23M$59.13M
Surprise %20.96%-5.66%8.16%8.08%125.78%---

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$528.58M$515.84M$-615.06M$-521.96M$-437.99M---
Avg Forecast$341.01M$396.47M$-615.06M$-533.34M$-535.68M$-467.09M$-346.71M$-256.89M
High Forecast$669.82M$719.43M$-114.04M$-491.49M$-347.75M$-396.77M$-247.65M$8.90M
Low Forecast$12.20M$73.51M$-1.12B$-533.99M$-604.56M$-537.42M$-445.77M$-523.24M
Surprise %55.00%30.11%--2.13%-18.24%---

VIR Forecast FAQ

Is Vir Bio stock a buy?

Vir Bio stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vir Bio is a favorable investment for most analysts.

What is Vir Bio's price target?

Vir Bio's price target, set by 12 Wall Street analysts, averages $21.29 over the next 12 months. The price target range spans from $18 at the low end to $30 at the high end, suggesting a potential 116.80% change from the previous closing price of $9.82.

How does Vir Bio stock forecast compare to its benchmarks?

Vir Bio's stock forecast shows a 116.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vir Bio over the past three months?

  • March 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Vir Bio’s EPS forecast?

Vir Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.44, marking a 8.86% increase from the reported $-3.16 in 2025. Estimates for the following years are $-2.78 in 2027, and $-1.92 in 2028.

What is Vir Bio’s revenue forecast?

Vir Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $32.45M, reflecting a -52.67% decrease from the reported $68.56M in 2025. The forecast for 2027 is $84.42M, and $289.68M for 2028.

What is Vir Bio’s net income forecast?

Vir Bio's net income forecast for the fiscal year ending in December 2026 stands at $-467M, representing an 6.65% increase from the reported $-438M in 2025. Projections indicate $-347M in 2027, and $-257M in 2028.